Today UBS Reiterates a “Buy” Rating on Sucampo Pharmaceuticals (NASDAQ:SCMP) and a $15 Target Price

October 13, 2017 - By Stephen Andrade

 Today UBS Reiterates a

Investors sentiment decreased to 1.33 in 2017 Q2. Its down 0.06, from 1.39 in 2017Q1. It worsened, as 23 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 59 raised stakes. 24.71 million shares or 3.79% less from 25.68 million shares in 2017Q1 were reported.

Invesco Ltd has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 64,515 shares. Creative Planning holds 0% or 2,003 shares in its portfolio. Pitcairn invested in 14,085 shares or 0.02% of the stock. Qs Ltd Liability Com, a New York-based fund reported 116,067 shares. Ls Investment Advisors Ltd Company stated it has 4,965 shares. Fifth Third Retail Bank reported 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). California Employees Retirement Systems reported 0% stake. Sabby Mgmt Limited Co accumulated 0.02% or 33,200 shares. Glenmede Tru Co Na stated it has 225 shares. Employees Retirement Association Of Colorado holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 8,353 shares. 55,496 were reported by Nuveen Asset Limited Liability Company. Malaga Cove Cap Limited Liability Company invested in 84,241 shares or 0.53% of the stock. Numeric Invsts Limited Liability holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 47,500 shares. Jpmorgan Chase & accumulated 11,141 shares. Clark Estates accumulated 0.45% or 250,000 shares.

Sucampo Pharmaceuticals (NASDAQ:SCMP) Rating Reaffirmed

Investment analysts at UBS now has a $15 price target on Sucampo Pharmaceuticals (NASDAQ:SCMP). UBS and their recent price target means a potential upside of 47.78 % from the company’s previous close. The rating has been revealed to investors in analysts note on Thursday morning.

Investors sentiment decreased to 1.33 in 2017 Q2. Its down 0.06, from 1.39 in 2017Q1. It worsened, as 23 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 59 raised stakes. 24.71 million shares or 3.79% less from 25.68 million shares in 2017Q1 were reported.

Invesco Ltd has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 64,515 shares. Creative Planning holds 0% or 2,003 shares in its portfolio. Pitcairn invested in 14,085 shares or 0.02% of the stock. Qs Ltd Liability Com, a New York-based fund reported 116,067 shares. Ls Investment Advisors Ltd Company stated it has 4,965 shares. Fifth Third Retail Bank reported 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). California Employees Retirement Systems reported 0% stake. Sabby Mgmt Limited Co accumulated 0.02% or 33,200 shares. Glenmede Tru Co Na stated it has 225 shares. Employees Retirement Association Of Colorado holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 8,353 shares. 55,496 were reported by Nuveen Asset Limited Liability Company. Malaga Cove Cap Limited Liability Company invested in 84,241 shares or 0.53% of the stock. Numeric Invsts Limited Liability holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 47,500 shares. Jpmorgan Chase & accumulated 11,141 shares. Clark Estates accumulated 0.45% or 250,000 shares.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Coverage

Among 9 analysts covering Sucampo Pharma (NASDAQ:SCMP), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Sucampo Pharma has $31 highest and $11.0 lowest target. $21.33’s average target is 110.15% above currents $10.15 stock price. Sucampo Pharma had 31 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Mizuho on Tuesday, October 3. The firm has “Mkt Perform” rating given on Thursday, September 3 by Leerink Swann. Jefferies maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Thursday, August 4. Jefferies has “Hold” rating and $14 target. On Thursday, August 6 the stock rating was maintained by WallachBeth Capital with “Hold”. The company was maintained on Monday, January 18 by Mizuho. Mizuho maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Monday, November 14. Mizuho has “Neutral” rating and $16 target. The rating was maintained by WallachBeth Capital with “Hold” on Thursday, August 27. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Hold” rating given on Friday, June 9 by Jefferies. Maxim Group maintained the stock with “Buy” rating in Tuesday, November 15 report. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Buy” rating given on Wednesday, August 26 by Maxim Group.

About 513,583 shares traded. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has declined 5.30% since October 13, 2016 and is downtrending. It has underperformed by 22.00% the S&P500.

Analysts expect Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report $0.25 EPS on November, 8.They anticipate $0.03 EPS change or 10.71 % from last quarter’s $0.28 EPS. SCMP’s profit would be $11.70M giving it 10.15 P/E if the $0.25 EPS is correct. After having $0.28 EPS previously, Sucampo Pharmaceuticals, Inc.’s analysts see -10.71 % EPS growth.

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $474.84 million. The Firm is focused on the development and commercialization of pharmaceutical products. It currently has negative earnings. The Company’s primary focus areas are gastroenterology, ophthalmology and oncology-related disorders.

More recent Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) news were published by: Globenewswire.com which released: “Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 …” on September 19, 2017. Also Seekingalpha.com published the news titled: “Sucampo Firing Sales Torpedos” on September 07, 2017. Bizjournals.com‘s news article titled: “Md. biotech expands HQ in ramp-up for potential drug approval” with publication date: September 19, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.